MX2021011118A - Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2. - Google Patents
Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2.Info
- Publication number
- MX2021011118A MX2021011118A MX2021011118A MX2021011118A MX2021011118A MX 2021011118 A MX2021011118 A MX 2021011118A MX 2021011118 A MX2021011118 A MX 2021011118A MX 2021011118 A MX2021011118 A MX 2021011118A MX 2021011118 A MX2021011118 A MX 2021011118A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- prc2
- azolopyridine
- eed
- macrocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
Abstract
La invención se refiere a moduladores del desarrollo de ectodermo embrionario (EED) y/o complejo represivo Polycomb 2 (PRC2) útiles en el tratamiento de trastornos y enfermedades asociados con EEC y PRC2, los cuales son derivados de azolopiridina macrocíclicos y composiciones de los mismos de la Fórmula I:(Ver Fòrmula I, o una sal, profármaco, solvato, hidrato, enantiómero, isómero o tautómero farmacéuticamente aceptable de los mismos, en donde X1, X2, X3, A1, A2, Y, R1, R2, R3 y R4 son como se describen en el presente documento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962819064P | 2019-03-15 | 2019-03-15 | |
PCT/US2020/022724 WO2020190754A1 (en) | 2019-03-15 | 2020-03-13 | Macrocyclic azolopyridine derivatives as eed and prc2 modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021011118A true MX2021011118A (es) | 2022-01-18 |
Family
ID=70228838
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021011118A MX2021011118A (es) | 2019-03-15 | 2020-03-13 | Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2. |
Country Status (13)
Country | Link |
---|---|
US (4) | US10973805B2 (es) |
EP (1) | EP3938050A1 (es) |
JP (1) | JP2022525199A (es) |
KR (1) | KR20210151833A (es) |
CN (1) | CN114144230B (es) |
AU (1) | AU2020241254A1 (es) |
BR (1) | BR112021018238A2 (es) |
CA (1) | CA3133751A1 (es) |
IL (1) | IL286433A (es) |
MX (1) | MX2021011118A (es) |
SG (1) | SG11202110092PA (es) |
TW (1) | TW202102495A (es) |
WO (1) | WO2020190754A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3691620T (pt) | 2017-10-05 | 2022-10-06 | Fulcrum Therapeutics Inc | Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd |
MX2021011118A (es) * | 2019-03-15 | 2022-01-18 | Fulcrum Therapeutics Inc | Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2. |
WO2022212748A1 (en) * | 2021-04-02 | 2022-10-06 | Fulcrum Therapeutics, Inc. | Polymorphic forms of (s)-12-fluoro-4-(1-methyl-1h-pyrazol-5-yl)-7a,8,13,14-tetrahydro-7h-[1,2,4]triazolo[4',3':1,6]pyrido[3,2-b]benzofuro[4,3-fg][1,4]oxazonine |
CA3214211A1 (en) * | 2021-04-02 | 2022-10-06 | Steven M. MENNEN | Macrocyclic azolopyridines |
CN115490708A (zh) * | 2021-06-18 | 2022-12-20 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
WO2023049723A1 (en) * | 2021-09-24 | 2023-03-30 | Oric Pharmaceuticals, Inc. | Prc2 inhibitors for use in treating blood disorders |
WO2023049724A1 (en) * | 2021-09-24 | 2023-03-30 | Oric Pharmaceuticals, Inc. | Prc2 inhibitors for use in treating blood disorders |
WO2023192415A1 (en) * | 2022-03-29 | 2023-10-05 | Fulcrum Therapeutics, Inc. | An embryonic ectoderm development inhibitor for the treatment of sickle cell disease |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
AU2012315566A1 (en) * | 2011-09-30 | 2014-04-17 | Glaxosmithkline Llc | Methods of treating cancer |
CN104245699B (zh) | 2011-11-03 | 2017-06-27 | 米伦纽姆医药公司 | Nedd8‑活化酶抑制剂和低甲基化剂的投与 |
SI3237418T1 (sl) * | 2014-12-23 | 2019-06-28 | Novartis Ag | Spojine triazolopirimidina in njihove uporabe |
CN109790166A (zh) * | 2016-06-20 | 2019-05-21 | 诺华股份有限公司 | 咪唑并吡啶化合物用于治疗癌症 |
ES2798424T3 (es) * | 2016-06-20 | 2020-12-11 | Novartis Ag | Compuestos de triazolopiridina y usos de estos |
WO2018013929A1 (en) | 2016-07-15 | 2018-01-18 | Tufts Medical Center | Compositions and methods for improving immune system function |
EP3573618B1 (en) | 2017-01-30 | 2023-08-16 | The Children's Hospital of Philadelphia | Compositions and methods for hemoglobin production |
ES2916449T3 (es) | 2017-04-10 | 2022-07-01 | Univ Michigan Regents | Inhibidores de DCN1 de molécula pequeña covalentes y métodos terapéuticos de uso de los mismos |
TW201920204A (zh) * | 2017-08-15 | 2019-06-01 | 美商艾伯維有限公司 | 大環mcl-1抑制劑以及使用方法 |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
EP3883597A2 (en) | 2018-11-20 | 2021-09-29 | Fulcrum Therapeutics, Inc. | Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease |
MX2021011118A (es) | 2019-03-15 | 2022-01-18 | Fulcrum Therapeutics Inc | Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2. |
WO2022212748A1 (en) | 2021-04-02 | 2022-10-06 | Fulcrum Therapeutics, Inc. | Polymorphic forms of (s)-12-fluoro-4-(1-methyl-1h-pyrazol-5-yl)-7a,8,13,14-tetrahydro-7h-[1,2,4]triazolo[4',3':1,6]pyrido[3,2-b]benzofuro[4,3-fg][1,4]oxazonine |
CA3214211A1 (en) | 2021-04-02 | 2022-10-06 | Steven M. MENNEN | Macrocyclic azolopyridines |
WO2022232435A1 (en) | 2021-04-29 | 2022-11-03 | Fulcrum Therapeutics, Inc. | Methods of regulating bcl11a expression and treatment of bcl11a-mediated disorders |
-
2020
- 2020-03-13 MX MX2021011118A patent/MX2021011118A/es unknown
- 2020-03-13 CN CN202080033787.5A patent/CN114144230B/zh active Active
- 2020-03-13 KR KR1020217033290A patent/KR20210151833A/ko unknown
- 2020-03-13 TW TW109108410A patent/TW202102495A/zh unknown
- 2020-03-13 BR BR112021018238A patent/BR112021018238A2/pt unknown
- 2020-03-13 AU AU2020241254A patent/AU2020241254A1/en active Pending
- 2020-03-13 JP JP2021555455A patent/JP2022525199A/ja active Pending
- 2020-03-13 CA CA3133751A patent/CA3133751A1/en active Pending
- 2020-03-13 EP EP20718058.9A patent/EP3938050A1/en active Pending
- 2020-03-13 SG SG11202110092PA patent/SG11202110092PA/en unknown
- 2020-03-13 WO PCT/US2020/022724 patent/WO2020190754A1/en active Application Filing
- 2020-04-24 US US16/858,404 patent/US10973805B2/en active Active
-
2021
- 2021-02-18 US US17/178,637 patent/US11590111B2/en active Active
- 2021-09-14 IL IL286433A patent/IL286433A/en unknown
-
2022
- 2022-12-20 US US18/085,134 patent/US20240139163A1/en active Pending
-
2023
- 2023-04-27 US US18/140,527 patent/US20240075016A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112021018238A2 (pt) | 2021-12-28 |
SG11202110092PA (en) | 2021-10-28 |
JP2022525199A (ja) | 2022-05-11 |
US20240075016A1 (en) | 2024-03-07 |
CN114144230B (zh) | 2024-04-23 |
US20240139163A1 (en) | 2024-05-02 |
US11590111B2 (en) | 2023-02-28 |
US20220160686A1 (en) | 2022-05-26 |
IL286433A (en) | 2021-10-31 |
CN114144230A (zh) | 2022-03-04 |
TW202102495A (zh) | 2021-01-16 |
US10973805B2 (en) | 2021-04-13 |
US20200360353A1 (en) | 2020-11-19 |
AU2020241254A1 (en) | 2021-10-07 |
KR20210151833A (ko) | 2021-12-14 |
CA3133751A1 (en) | 2020-09-24 |
EP3938050A1 (en) | 2022-01-19 |
WO2020190754A1 (en) | 2020-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021011118A (es) | Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2. | |
MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
PH12020500125A1 (en) | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | |
PH12020551305A1 (en) | Pharmaceutical Compounds | |
CR20210001A (es) | Derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona y su uso en el tratamiento de trastornos dependientes de la proteina con dedos de zinc 2 de la familia ikaros (1kzf2) | |
MX2023001876A (es) | Derivados de rapamicina. | |
MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
GEP20084439B (en) | Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof | |
MX2022003102A (es) | Degradadores bifuncionales de brd9 y sus metodos de uso. | |
MY167135A (en) | Fused heterocyclic derivatives and methods of use | |
MX2009003874A (es) | Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos. | |
WO2008046087A3 (en) | Spiro compounds and their uses as therapeutic agents | |
MX2013011589A (es) | Metodos y composiciones para tratar enfermedad de parkinson. | |
PH12019550140A1 (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
AU2018253590A1 (en) | Imidazopyridazine compounds | |
MX2009009466A (es) | Compuestos triciclicos de utilidad en el tratamiento de trastornos del hierro. | |
MX2020012058A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cancer. | |
MX2021007247A (es) | Derivados de rapamicina. | |
MX2021012105A (es) | Compuestos de pirrol. | |
ZA202006071B (en) | Antiproliferation compounds and uses thereof | |
PH12020551343A1 (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer | |
CR20220160A (es) | Derivados de piridazin-3(2h)-ona fusionados con azol | |
MX2022006333A (es) | Compuesto triheterociclico como inhibidor de jak y uso del mismo. |